SeeThruEquity Issues Update on BioSig Technologies, Inc. (OTCQB: BSGM), Highlighting Company’s Technology Being Featured in Mayo Clinic Research

NEW YORK, NY / ACCESSWIRE / August 18, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on BioSig Technologies, Inc. (OTCQB: BSGM).

The report is available here: BSGM August 2016 Update Note.

“We see the publication as a major milestone for BioSig, introducing the technology to the industry through research conducted with the Mayo Clinic, one of the most prestigious institutions in medicine. We see the article as evidence management is making progress on its stated goals for 2016, and we are looking forward to additional peer-reviewed journals and industry presentations in the future,” commented Ajay Tandon, CEO of SeeThruEquity.

Additional highlights from the update include the following:

BioSig achieves major milestone with publication along with Mayo Clinic in leading peer-reviewed publication JACC

BioSig management had stated in an annual letter to investors and stakeholders that it would be introducing the PURE EP System™ to leading industry participants in 2016, and the company continues to follow through on this commitment. In early August, BioSig announced that its lead device, the PURE EP System™, was featured in a research article by researchers from the prestigious Mayo Clinic that was published in The Journal of the American College of Cardiology (JACC): Clinical Electrophysiology, a leading peer-reviewed publication focused on care and heart health in the area of cardiac electrophysiology. Authored by Dr. Samuel Asirvatham, Vice Chair of Cardiovascular Diseases and program director of Clinical Cardiac Electrophysiology Training Program at the Mayo Clinic in Rochester, MN, the article represents the first piece about PURE EP™ in a peer-reviewed publication and is a significant milestone for the company.

Article highlights advantages versus standard EP recording systems

BioSig’s PURE EP System is a high fidelity surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system, which is designed to improve the process of identifying catheter ablation targets – areas of tissue to destroy that otherwise create a cardiac arrhythmia. The article appearing in JACC: Clinical Electrophysiology featuring BioSig’s PURE EP™ was entitled “Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals” and highlighted the advantages of BioSig’s proprietary PURE EP™ technology versus standard EP recording systems, particularly for the analysis of high frequency signals (ie, Purkinjie potentials). Dr. Asirvatham also noted PURE EP’s capability to show the same channel with different processing options, enabling doctors to highlight specific features while still displaying the original electrogram signal. In our view, the article is a major event for the company, providing peer-reviewed journal validation for the company’s innovative approach to a $3.5 billion market opportunity while elevating its profile and garner increased industry attention to the advantages of the PURE EP™ System.

Maintain price target of $3.53 for BioSig

We have been encouraged by the progress made by BioSig since our initiation of coverage in February 2016 and note that shares have risen by more than 25% in that time. We see several opportunities ahead for BioSig and are maintaining a price target of $3.53 at this time.

Please review important disclosures at www.seethruequity.com.

About BioSig Technologies, Inc.

BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3 billion electrophysiology (EP) marketplace1 (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.

PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets — areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).

Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 20191 — making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 20172.

BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation’s most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.

1) Electrophysiology Devices Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

2) HRI 2013 “Global Opportunities in Medical Devices & Diagnostics” report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 443966